The process of epithelial–mesenchymal transition (EMT) is fundamental for embryonic
morphogenesis. Cells undergoing it lose epithelial characteristics and integrity, acquire …

Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …

Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Metastasis is the most frequent cause of death in cancer patients. Epithelial-to-mesenchymal
transition (EMT) is the process in which cells lose epithelial integrity and become motile, a …

Several lines of compelling pre-clinical evidence identify chemotherapy as a potentially
double-edged sword: therapeutic efficacy on the primary tumor may in fact be …

Tumors invade the surrounding tissues to progress, but the heterogeneity of cell types at the
tumor-stroma interface and the complexity of their potential interactions hampered …

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by
aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still …

Epithelial mesenchymal transition (EMT) is a complex process through which epithelial (E)
cells lose their adherens junctions, transform into mesenchymal (M) cells and attain motility …

Epithelial–mesenchymal transitions (EMTs) generate hybrid phenotypes with an enhanced
ability to adapt to diverse microenvironments encountered during the metastatic spread …

Resistance to radiotherapy (IR), with consequent disease recurrence, continues to limit the
efficacy of contemporary anticancer treatment for patients with hepatocellular carcinoma …